Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on ResMed

Related RMD
40 Biggest Movers From Yesterday
Mid-Afternoon Market Update: Crude Oil Up 1.4%; ResMed Shares Rise On Earnings Beat

In a report published Monday, Jefferies & Company reiterated its Hold rating on ResMed (NYSE: RMD), and slightly raised its price target from $34.00 to $35.00.

Jefferies noted, “RMD reported mixed FQ1 results with US Masks and Intl generators missing the mark on US reimbursement nuances, competition, and F/X. Runway still looks clear for volume gains on HST and cardio adoption while further margin expansion is possible from mix and Shanghai manufacturing. However, pricing and comp bidding are still questions and valuation still a little rich. PT to $35 but rating stays at Hold.”

ResMed closed on Friday at $39.92.

Latest Ratings for RMD

Jan 2018NeedhamUpgradesUnderperformHold
Oct 2017JP MorganMaintainsOverweight
Oct 2017BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (RMD)

View Comments and Join the Discussion!